Abstract
Piroxantrone demonstrated no activity in 17 eligible patients. Toxicity was acceptable and dose escalations were performed. With only 35% (6/17) of patients experiencing grade 2 or greater granulocytopenia the study might be criticized for utilizing a less than optimal dose of piroxantrone. Based on this trial, piroxantrone is not felt to have significant antitumor activity against advanced non-small cell carcinoma of the lung.
Original language | English (US) |
---|---|
Pages (from-to) | 29-30 |
Number of pages | 2 |
Journal | Investigational New Drugs |
Volume | 10 |
Issue number | 1 |
DOIs | |
State | Published - Mar 1992 |
Keywords
- lung cancer
- non-small cell
- phase II
- piroxantrone
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)